Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial

doi:10.2196/46101

Published on 16.6.2023 in Vol 12 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/46101, first published January 31, 2023.

$Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial$

Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial

Zheyi Dong^{1, 2, 3, 4, 5}

; Jianhui Zhou^{1, 2, 3, 4, 5}

; Zhonggao Xu⁶

; Zhaohui Ni⁷

; Yani He⁸

; Hongli Lin^{9, 10}

; Gengru Jiang¹¹

; Xuefeng Sun^{1, 2, 3, 4, 5}

; Li Zhang^{1, 2, 3, 4, 5}

; Xiangmei Chen^{1, 2, 3, 4, 5}

Article Authors Cited by Tweetations (2) Metrics

Altmetric

Altmetric discovers Social Media mentions. Click the ‘See more details’ link for a full report.

This paper is in the following e-collection/theme issue:

Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial

Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial

Altmetric

Dimensions

Metrics Since Publication